Equities

ALCAR

FR0010907956

Medical Equipment, Supplies & Distribution

Real-time Euronext Paris Other stock markets 06:38:05 2024-04-24 am EDT			5-day change	1st Jan Change
3.79 ^EUR	+0.26%		-0.26%	-43.43%

Mar. 25	Carmat: final agreement with creditors	CF
Mar. 25	Carmat Secures Two-year Extensions for Bank Loans	MT

Carmat SA Reports Earnings Results for the Full Year Ended December 31, 2021

February 16, 2022 at 01:00 am EST

Carmat SA reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was EUR 2.2 million. Net loss was EUR 61.9 million compared to EUR 37 million a year ago.

Latest news about CARMAT

Carmat: final agreement with creditors	Mar. 25	CF
Carmat Secures Two-year Extensions for Bank Loans	Mar. 25	MT
CARMAT Announces a Final Agreement with All Its Financial Creditors on New Repayment Terms for Its Bank Loans	Mar. 22	CI
Carmat: up sharply, broker upgrades to 'buy	Feb. 01	CF
CARMAT : Invest Securities upgrades to 'buy'.	Feb. 01	CF
Oddo BHF Keeps Carmat at Neutral, Cuts PT	Jan. 29	MT
France’s Carmat Secures EUR17 Million via Capital Raise; Shares Fall	Jan. 29	MT
CARMAT : price target lowered by Oddo BHF	Jan. 29	CF
Carmat: capital increase completed	Jan. 29	CF
Carmat SA announced that it has received ?16.5186 million in funding	Jan. 28	CI
CARMAT : Invest Securities advises to subscribe	Jan. 18	CF
Transcript : Carmat SA - Special Call	Jan. 17
Carmat: launches a capital increase	Jan. 17	CF
Carmat SA announced that it expects to receive ?15.000002 million in funding	Jan. 16	CI
Carmat: has passed the 50-implant milestone	Jan. 15	CF
Artificial heart maker Carmat to launch capital increase soon	Jan. 15	RE
Carmat Sa Provides Sales Guidance for the Year 2024	Jan. 15	CI
Carmat: conditional agreement in principle with the EIB	Jan. 12	CF
Carmat Secures In-principle Extension for European Investment Bank Loan	Jan. 12	MT
Carmat SA Announces Conditional Agreement in Principle with the EIB on New Loan Repayment Terms	Jan. 12	CI
CAC40: modest rise in non-existent volumes	Dec. 29	CF
CAC40: stalls below 7,570, W-Street crumbles, OAT tension	Dec. 29	CF
CAC40: attempts to cling to 7,570, sharp rise in OAT/Bund rates	Dec. 29	CF
CAC40: a slight rise, with the luxury sector providing support	Dec. 29	CF
Carmat Announces Software Enhancement for Artificial Heart	Dec. 29	MT

Chart CARMAT

Duration

Period

More charts

Company Profile

CARMAT specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnostics system. The artificial heart is intended for patients with advanced cardiac insufficiency who are ineligible for a transplant and have exhausted all medication alternatives.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-04-23 - Q4 2023 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for CARMAT

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.78 EUR

Average target price

14.22 EUR

Spread / Average Target

+276.19%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Devices & Implants

	1st Jan change	Capi.
CARMAT	-43.43%	100M
STRYKER CORPORATION	+11.84%	127B
SMITH & NEPHEW PLC	-8.28%	10.68B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	-1.71%	8.59B
INSPIRE MEDICAL SYSTEMS, INC.	+14.99%	7.09B
GLAUKOS CORPORATION	+27.16%	5.07B
AXONICS, INC.	+6.81%	3.39B
ENOVIS CORPORATION	-0.98%	3.04B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	-13.77%	2.02B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-9.83%	2B

Medical Devices & Implants